Genetic Leap blog

Sign in Subscribe

Genetic Leap to present at upcoming conferences

Genetic Leap to present at upcoming conferences

Bertrand Adanve, CEO and Founder of Genetic Leap, will present at BIO CEO & Investor conference on February 6 in New York and at the RNA World Leaders conference on March 15 in Basel.

Genetic Intelligence is now Genetic Leap

Genetic Intelligence is now Genetic Leap

With our RNA-targeted capabilities bringing us closer to our full vision, we have adopted a name that better describes our overall capabilities.

Experimental validation

Experimental validation

For AI predictions of complex biological phenomena, experimental validation is the ultimate proof of correctness. But experimental validation is itself subject to myriad factors and considerations that can lead to spurious outcomes if not carefully addressed.

Interpreting whole genome variants

Interpreting whole genome variants

Actionable target selection is a critical drug discovery challenge that requires solving not only the whole genome’s noise and sample size problems, but also interpreting variants outside the exome. Achieving these lead to an expansion of what it means for a target to be genetically-defined.

Drugging the RNA: part I, Why do it?

Drugging the RNA: part I, Why do it?

In part I of a series of posts discussing how to drug RNA, we discuss the three dimensions on which a disease target can be drugged, and how RNA’s dual role as both blueprint and object confers it unique properties that make it a particularly attractive target dimension over protein and DNA.

Welcome to Larry Senour

Welcome to Larry Senour

We are excited to welcome Larry Senour to Genetic Intelligence to help lead business development. Larry has 30 years of healthcare experience in strategy, operations and transaction roles, including 23 years with Merck & Co., Inc. In his last role at Merck he was Managing Director of Healthcare Services &

VIDEO: Experience Genetic Intelligence

VIDEO: Experience Genetic Intelligence

Watch the Genetic Intelligence vision. Genetic Intelligence finds truly causal disease targets and designs medicines to fix them. With Genetic Intelligence, you can step into the future of drug discovery. You can take in all of the interconnected parts of your program in full clarity. You can drive better collaboration,

An Introduction to Andy Ng

An Introduction to Andy Ng

“Successful problem solving requires finding the right solution to the right problem. We fail more often because we solve the wrong problem than because we get the wrong solution to the right problem.” - Russell L. Ackoff

Introduction to David Young: Working to Shift the Genetics Paradigm

Introduction to David Young: Working to Shift the Genetics Paradigm

Life can be tragic, full of pain, disease, and death. We live in a world surrounded by these horrors that gnaw at the bones of our very existence. But why should we accept it as the default? Can we not ease the suffering of this world? Disease has been caught

An introduction to Andrew Young

An introduction to Andrew Young

I have always been curious about the design of truly impactful products and software, and how they can change the dynamics of a market. These passions led me to pursue mechanical engineering at the Massachusetts Institute of Technology (MIT) with a focus on entrepreneurship. At MIT where I was also

5,000 Alzheimer's disease WGS Access

5,000 Alzheimer's disease WGS Access

Genetic Intelligence access to 5,000 AD WGS

How people of the future will see today's medicine

Genetic Leap Featured

How people of the future will see today's medicine

The past world was gripped with apocalyptic fears where most things were explained with imaginative tales of demons and witches. In this backdrop, terrifying outbreaks killed millions. People of the future will look back on our time with the same incredulity we look at these past times.

Solving the rate-limiting steps of drug discovery

Genetic Leap Featured

Solving the rate-limiting steps of drug discovery

Drug development is arduous and lengthy. That difficulty is reflected in the price of medicine as high drug prices. But the story would be very different and relief brought to all stakeholders if the rate limiting step in the drug discovery process can be solved.

Genome analysis strategies: a closer look at layer III of the genomic space

Genome analysis strategies: a closer look at layer III of the genomic space

In this follow-up to our practical overview of the genomic space, we take a closer look at layer III and the considerations that impel its genomic analysis strategies.

A Brief Overview of the Genomic Space

A Brief Overview of the Genomic Space

The genomic space is currently teeming with a lot of welcomed activity. But there can also be confusion as to which player is doing what. To help provide clarity to more stakeholders, we synthesized a practical overview of the space.

Shifting perspectives on our WGS and lower sample numbers focus

Shifting perspectives on our WGS and lower sample numbers focus

Increasingly, we are seeing the genetic field slowly pivot toward the path we at GI have insisted on (and blazed) all along. Namely, 1) whole genome (WGS) instead of whole exome (WES) and 2) well characterized cohorts (which can mean smaller number of samples) instead of larger and larger studies.

Genetic data samples size: bigger is not better

Genetic data samples size: bigger is not better

Most genome analysis efforts are pursuing the “more data, bigger GWAS” strategy to solve the herculean causal gene discovery challenge. But this approach is infeasible on many levels. Rather, actionable disease genes can be identified using a small number of well-structured, well-defined samples.

Genetic data type: whole genome or whole exome?

Genetic data type: whole genome or whole exome?

The genomic industry has favored whole exome (WES) due to cost and analysis difficulties, but the secrets of the genome reside in the whole genome (WGS). Those who can innovate to solve the herculean WGS analysis challenge will unlock tremendous value for their stakeholders and society.

Genetic Intelligence awarded Competitive grant from the National Science Foundation

Genetic Intelligence awarded Competitive grant from the National Science Foundation

Genetic Intelligence has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $225,000 to conduct research and development (R&D) work on causal disease gene identification from Whole Genomes using Artificial Intelligence

Welcome to the Genetic Intelligence Brief

Getting Started

Welcome to the Genetic Intelligence Brief

The GI Brief is designed to be concise, accessible, and bearer of answers. Let's jump in.